Skip to main content

Advertisement

SpringerLink
Log in

Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg−1 day−1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence of grade III–IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among the patients with solid tumours (p = 0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological recovery. According to the present study design and taking into account the current prices in our institution, the cost of the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with haematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883

    Article  PubMed  CAS  Google Scholar 

  2. Villanueva ML, Vose JM (2006) The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol 4:521–530

    PubMed  Google Scholar 

  3. Hiddemann W, Buske C, Dreyling M et al (2005) Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 23:6394–6399

    Article  PubMed  CAS  Google Scholar 

  4. Connors JM (2005) State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 23:6400–6408

    Article  PubMed  CAS  Google Scholar 

  5. Rodenhuis S, Bontenbal M, Beex LVAM et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7–16

    Article  PubMed  CAS  Google Scholar 

  6. Nitz UA, Mohrmann S, Fischer J et al (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial (for the West German Study Group). Lancet 366:1935–1944

    Article  PubMed  CAS  Google Scholar 

  7. Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 3:CD003142

    PubMed  Google Scholar 

  8. Kirk JL Jr, Greenfield RA, Slease RB, Epstein RB (1988) Analysis of early infectious complications after autologous bone marrow transplantation. Cancer 62:2445–2450

    Article  PubMed  Google Scholar 

  9. Toor AA, van Burik JA, Weisdorf DJ (2001) Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 28:1129–1134

    Article  PubMed  CAS  Google Scholar 

  10. Klumpp TR, Goldberg SL, Mangan KF (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 13:1323–1327

    PubMed  CAS  Google Scholar 

  11. Hornedo J, Sola C, Solano C et al (2002) The role of granulocyte colony stimulating factor (G-CSF) in the post-transplant period (SOLTI Group). Bone Marrow Transplant 29:737–743

    Article  PubMed  CAS  Google Scholar 

  12. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907–1929

    PubMed  CAS  Google Scholar 

  13. Lord BI, Woolford LB, Molineux G (2001) Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (Peg-r-metHu G-CSF). Clin Cancer Res 7:2085–2090

    PubMed  CAS  Google Scholar 

  14. Molineux G (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF). Curr Pharm Des 10:1235–1244

    Article  PubMed  CAS  Google Scholar 

  15. Molineux G, Kinstler O, Briddell B et al (1999) A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724–1734

    Article  PubMed  CAS  Google Scholar 

  16. Holmes FA, Jones SE, O’Shaughnessy J et al (2002) Comparable efficacy and safety profile of once per cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909

    Article  PubMed  CAS  Google Scholar 

  17. Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731

    Article  PubMed  CAS  Google Scholar 

  18. Vose JM, Crump M, Lazarus H et al (2003) Randomized, multicenter, open-label study of filgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514–519

    Article  PubMed  CAS  Google Scholar 

  19. Steidl U, Fenk R, Bruns I et al (2005) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35:33–36

    Article  PubMed  CAS  Google Scholar 

  20. George S, Yunus F, Case D et al (2003) Fixed dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 44:1691–1996

    Article  PubMed  CAS  Google Scholar 

  21. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M (2006) Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42:2976–2981

    Article  PubMed  CAS  Google Scholar 

  22. Jagasia MH, Greer JP, Morgan DS et al (2005) Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Tranplant 35:1165–1169

    Article  CAS  Google Scholar 

  23. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P (2005) Fixed dose single administration of pegfilgrastim vs daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35:889–893

    Article  PubMed  CAS  Google Scholar 

  24. Musto P, Scalzulli PR, Melillo L et al (2004) Peg-filgrastim after autologous peripheral blood stem cell transplantation in haematological malignancies. Blood 104:Abst 5200

    Google Scholar 

  25. Vanstraelen G, Frère P, Ngirabacu MC, Willems E, Fillet G, Beguin Y (2006) Pegfilgrastim compared with filgrastim after autologous haematopoietic peripheral blood stem cell transplantation. Exp Hematol 34:382–388

    Article  PubMed  CAS  Google Scholar 

  26. Martino M, Praticò G, Messina G et al (2006) Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 77:410–415

    Article  PubMed  CAS  Google Scholar 

  27. Patrone F, Ballestrero A, Ferrando F et al (1995) Four step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 13:840–846

    PubMed  CAS  Google Scholar 

  28. Gianni A, Bonadonna G (2001) Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). In: Grunberg SM (ed) Proceedings of the 37th annual meeting of the American Society of Clinical Oncology. San Francisco, CA, USA, Abstr 80

  29. Zander AR, Kröger N, Schmoor C et al (2004) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22:2273–2283

    Article  PubMed  CAS  Google Scholar 

  30. Vaena DA, Abonour R, Einhorn L (2003) Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21:4100–4104

    Article  PubMed  CAS  Google Scholar 

  31. Chopra R, McMillan AK, Linch DC et al (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood 81:1137–1145

    PubMed  CAS  Google Scholar 

  32. Stewart DA, Bahlis N, Valentine K et al (2006) Upfront double high dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor prognosis aggressive non-Hodgkin lymphoma. Blood 107:4623–4627

    Article  PubMed  CAS  Google Scholar 

  33. Wang EH, Chen YA, Corringham S et al (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34:581–587

    Article  PubMed  CAS  Google Scholar 

  34. Yang BB, Lum PK, Hayashi MM, Roskos LK (2004) Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 93:1367–1373

    Article  PubMed  CAS  Google Scholar 

  35. Layton JE, Hockman H, Sheridan WP, Morstyn G (1989) Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74:1303–1307

    PubMed  CAS  Google Scholar 

  36. Kuwabara T, Kobayashi S, Sugiyama Y (1996) Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 28:625–658

    Article  PubMed  CAS  Google Scholar 

  37. Delgado C, Francis G, Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249–304

    PubMed  CAS  Google Scholar 

  38. Ng R, Green MD (2005) Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy. Expert Rev Anticancer Ther 5:585–590

    Article  PubMed  CAS  Google Scholar 

  39. Johnston E, Crawford J, Blackwell S et al (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522–2528

    PubMed  CAS  Google Scholar 

  40. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184

    Article  PubMed  CAS  Google Scholar 

  41. Livi L, Paiar F, Santini R et al (2006) Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer. Anti-Cancer Drugs 17:1081–1085

    Article  PubMed  CAS  Google Scholar 

  42. Isidori A, Tani M, Bonifazi F et al (2005) Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 90:225–231

    PubMed  CAS  Google Scholar 

  43. Nosari A, Cairoli R, Ciapanna D et al (2006) Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin–aracytin-containing regimens. Bone Marrow Tranplant 38:413–416

    Article  CAS  Google Scholar 

  44. Hosing C, Qazilbash MH, Kebriaei P et al (2006) Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533–537

    Article  PubMed  CAS  Google Scholar 

  45. Fenk R, Hieronimus N, Steidl U et al (2006) Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 34:1296–1302

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna, Università di Genova, Viale Benedetto XV 6, 16132, Genova, Italy

    Alberto Ballestrero, Davide Boy, Roberta Gonella, Maurizio Miglino, Marino Clavio, Valentina Barbero, Alessio Nencioni, Marco Gobbi & Franco Patrone

Authors
  1. Alberto Ballestrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Boy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberta Gonella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Miglino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marino Clavio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valentina Barbero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alessio Nencioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marco Gobbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Franco Patrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Ballestrero.

Additional information

Alberto Ballestrero and Davide Boy contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ballestrero, A., Boy, D., Gonella, R. et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 87, 49–55 (2008). https://doi.org/10.1007/s00277-007-0366-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-007-0366-7

Keywords

Search

Navigation